<DOC>
	<DOCNO>NCT00308581</DOCNO>
	<brief_summary>To assess clinical efficacy subcutaneous ( sc ) certolizumab pegol administration 26 week patient suffer Crohn 's Disease ( CD ) previously treat infliximab</brief_summary>
	<brief_title>Certolizumab Crohn 's Disease Patients With Loss Response Intolerance Infliximab</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Subjects Crohn 's Disease Previous treatment failure Infliximab ( intolerance and/or response ) Obstructive intestinal stricture Recent bowel resection Proctocolectomy total colectomy Current total parenteral nutrition Short bowel syndrome All concomitant diseases pathological condition could interfere Crohn 's disease assessment harmful well patient Previous clinical trial previous biological therapy could interfere result present clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Certolizumab pegol</keyword>
</DOC>